Navigation Links
Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
Date:7/13/2012

WOODCLIFF LAKE, N.J., July 13, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its operating subsidiary, Par Formulations Private Limited, (formerly Edict Pharmaceuticals Private Limited), received its first USFDA approval for Labetalol HCl Tablets 100 mg, 200 mg & 300 mg, the generic version of Trandate®.  Par anticipates the product to be available in August.

Par Pharmaceutical acquired Edict Pharmaceuticals, based in Chennai, India, in February 2012. 

Important information about Labetalol HCl Tablets
Labetalol hydrochloride tablets are indicated in the management of hypertension. Labetalol hydrochloride tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics.

Labetalol hydrochloride tablets are contraindicated in bronchial asthma, overt cardiac failure, greater-than-first-degree heart block, cardiogenic shock, severe bradycardia, other conditions associated with severe and prolonged hypotension, and in patients with a history of hypersensitivity to any component of the product.  Beta-blockers, even those with apparent cardioselectivity, should not be used in patients with a history of obstructive airway disease, including asthma.

About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company.  Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.  For press releases and other company information, visit www.parpharm.com.

Safe Harbor Statement
Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
2. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
3. GlaxoSmithKline Share Their Insight on Understanding DDI With a View to Better Prediction and Control
4. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
5. Integrity Life Sciences Receives CE Mark and ISO Certifications for the Integrity Spinal Care System Medical Device
6. Kimberly-Clark Health Care Receives FDA Clearance For KIMGUARD ONE-STEP Sterilization Wrap Portfolio With One-Year Maintenance Of Package Integrity And Amsco V-PRO maX (Flexible Cycle)
7. Dehaier Medical Receives Software Copyrights for Four Proprietary Technologies
8. Watsons Generic ARTHROTEC(R) Receives FDA Approval
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Asthmapolis Receives FDA Clearance for Asthma Inhaler Sensor Technology and Accompanying Software System
11. Integrity Life Sciences Receives US FDA 510(k) Clearance for its Integrity Spinal Care System Medical Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  Spiral Therapeutics, ... agreement with Bionure Farma, S.L. for the worldwide ... to BN119 in the field of otolaryngology for ... sales-based royalties. The agreement provides Spiral with ... with a differentiated product profile. Under the terms ...
(Date:3/29/2017)... HEIGHTS, Utah , March 29, 2017 /PRNewswire/ ... ) announced today the appointment of Cynthia ... Operations.  Cyndi will be responsible for leading Dynatronics ... organization and will report to Dynatronics, CEO ... Cyndi,s appointment concludes an extensive search process conducted ...
(Date:3/29/2017)... SPRING, Md. , March 29, 2017 On March ... (ocrelizumab) to treat adult patients with relapsing forms of ... This is the first drug approved by the FDA ... a health care professional.  "Multiple sclerosis ... said Billy Dunn , M.D., director of the ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 29, 2017 , ... Dr. Angela Cotey, a noted general dentist in Mt. ... patients, with or without a referral. Dr. Cotey knows that interceptive orthodontics ... experience. When patients receive early treatment, they may achieve straight teeth with less treatment ...
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
(Date:3/29/2017)... , ... March 29, 2017 ... ... and South Hills of Pittsburgh now have easier access to the robotic-assisted ... by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent Bellwether Education ... quality, the field must first improve teacher preparation program design. It then asserts ... and that decades of input- and outcome-based research has failed to improve teacher ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, ... be invited to the Siemens Healthineers annual customer education symposium, a world-class learning ... take place from March 27 - 31, 2017 at the Atlanta Marriott Marquis ...
Breaking Medicine News(10 mins):